Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

Abstract:

INTRODUCTION:Peripheral T cell lymphomas (PTCL) are a heterogenous group of lymphoproliferative disorders which are generally not curable with conventional chemotherapy and associated with inferior outcomes. Pralatrexate is a novel folate analog, the first FDA approved drug) for the treatment of relapsed/refractory (R/R) PTCL. AREAS COVERED:This paper provides a comprehensive review of PubMed literature describing the use of pralatrexate in R/R peripheral T-cell lymphoma. Pharmacokinetics and mechanism of action of pralatrexate are discussed as well as its clinical efficacy and safety in comparison to other agents available in R/R PTCL. EXPERT OPINION:Pralatrexate is an active agent in relapsed/refractory PTCL with lower response rates seen in patients with angioimmunoblastic T cell lymphomas. Mucositis is the most frequently observed adverse event and this can be mitigated by the use of leucovorin along with cyanocobalamin and folic acid.

journal_name

Expert Rev Hematol

authors

Jennifer C Z,Sara Mohamed J,Salma A,Francine F

doi

10.1080/17474086.2020.1756257

subject

Has Abstract

pub_date

2020-06-01 00:00:00

pages

577-583

issue

6

eissn

1747-4086

issn

1747-4094

journal_volume

13

pub_type

杂志文章
  • Advances in fertility preservation of female patients with hematological malignancies.

    abstract:INTRODUCTION:The most common forms of hematological malignancies that occur in female reproductive years are lymphoma and leukemia. Areas covered: Several aggressive gonadotoxic regimens such as alkylating chemotherapy and total body irradiation are used frequently in treatment of lymphoma and leukemia leading to subse...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2017.1371009

    authors: Salama M,Isachenko V,Isachenko E,Rahimi G,Mallmann P

    更新日期:2017-11-01 00:00:00

  • Andexanet alfa for the treatment of hemorrhage.

    abstract:INTRODUCTION:While associated life-threatening and fatal bleeding events are less frequent with the direct factor Xa inhibitors compared to vitamin K antagonists, significant concern surrounding management of major bleeds and urgent periprocedural interruption of these agents exists among clinicians. Andexanet alfa is ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1532287

    authors: Cervi A,Crowther M

    更新日期:2018-11-01 00:00:00

  • Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.

    abstract::Anti-CD20 monoclonal antibodies (mAbs), rituximab, ofatumumab and obinutuzumab, have a significant impact in the treatment of chronic lymphocytic leukemia (CLL), particularly in combination with chemotherapy. Over the last few years, several new mAbs have been developed and investigated in CLL. The most promising newe...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.963048

    authors: Robak T

    更新日期:2014-12-01 00:00:00

  • Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.

    abstract:INTRODUCTION:Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are considered indolent lymphocytic malignancies, more often requiring active surveillance rather than intervention. Despite the indolent nature of CLL/SLL, treatment is likely indicated in a patients' lifetime. Recent changes in the t...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1270203

    authors: Tees MT,Flinn IW

    更新日期:2017-02-01 00:00:00

  • Factor VIII therapy for hemophilia A: current and future issues.

    abstract::Hemophilia A is a congenital, recessive, X-linked bleeding disorder that is managed with infusions of plasma-derived or recombinant factor (F) VIII. The primary considerations in FVIII replacement therapy today are the: 1) immunogenicity of FVIII concentrates, 2) role of longer-acting FVIII products, 3) prophylactic u...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.899896

    authors: Aledort L,Ljung R,Mann K,Pipe S

    更新日期:2014-06-01 00:00:00

  • Incorporating placental tissue in cord blood banking for stem cell transplantation.

    abstract:INTRODUCTION:Human term placenta is comprised of various tissues from which different cells can be obtained, including hematopoietic stem cells and mesenchymal stem/stromal cells (MSCs). Areas covered: This review will discuss the possibility to incorporate placental tissue cells in cord blood banking. It will discuss ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1483717

    authors: Teofili L,Silini AR,Bianchi M,Valentini CG,Parolini O

    更新日期:2018-08-01 00:00:00

  • Iliopsoas hematomas in people with hemophilia: diagnosis and treatment.

    abstract:INTRODUCTION:Iliopsoas muscle hemorrhage in patients with hemophilia is a serious complication with relevant related morbidity. AREAS COVERED:A Cochrane Library and PubMed (MEDLINE) search of studies related to iliopsoas hematomas in hemophilia was analyzed. Pain in the hip joint area and femoral nerve involvement in ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1787146

    authors: Rodriguez-Merchan EC,De la Corte-Rodriguez H

    更新日期:2020-08-01 00:00:00

  • Mobilization of hematopoietic stem cells into the peripheral blood.

    abstract::Hematopoietic stem cells can be mobilized out of the bone marrow into the blood for the reconstitution of hematopoiesis following high-dose therapy. Methods to improve mobilization efficiency and yields are rapidly emerging. Traditional methods include chemotherapy with or without myeloid growth factors. Plerixafor, a...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.54

    authors: Damon LE,Damon LE

    更新日期:2009-12-01 00:00:00

  • Risk assessment of venous thromboembolism in hematological cancer patients: a review.

    abstract::Introduction: Venous thromboembolism (VTE) is a frequent and serious complication in cancer patients. Nonetheless, patients with hematological cancers receive less attention as compared with their solid tumor counterparts regarding this potentially fatal complication.Areas covered: Risk factors that are associated wit...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1751608

    authors: Chan TS,Hwang YY,Tse E

    更新日期:2020-05-01 00:00:00

  • Treatment of hairy cell leukemia.

    abstract:INTRODUCTION:Purine analogs made dramatic improvements for patients with hairy cell leukemia (HCL), but patients often relapse, require multiple treatments, and may become refractory. Major developments in treatment of relapsed/refractory HCL occurred with discovery of disease biology. New agents increase the complexit...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1819231

    authors: Chihara D,Kreitman RJ

    更新日期:2020-10-01 00:00:00

  • CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.

    abstract::Introduction: The genomic landscape of Waldenström macroglobulinemia (WM) is characterized by recurrent MYD88 (MYD88L265P) and CXCR4 mutations (CXCR4MUT), detected in 90% and 30% of cases, respectively. The role of CXCR4MUT in clinical features and outcomes to therapy in WM patients is evolving. Areas covered: We perf...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2019.1649132

    authors: Castillo JJ,Moreno DF,Arbelaez MI,Hunter ZR,Treon SP

    更新日期:2019-10-01 00:00:00

  • Novel targeted therapeutics for mantle cell lymphoma--what's on the horizon?

    abstract::Major advances have significantly improved the outcome of mantle cell lymphoma (MCL). Incorporation of rituximab to CHOP regimen, the adoption of high dose cytarabine with frontline autologous stem cell transplantation in young patients, maintenance rituximab or bortezomib based chemotherapy in elderly patients, impro...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2016.1134309

    authors: El Halabi L,Ghez D,Ribrag V

    更新日期:2016-03-01 00:00:00

  • How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.

    abstract:INTRODUCTION:Ruxolitinib is a potent and selective JAK1/JAK2 inhibitor that has shown superiority as compared to available conventional chemotherapies, in terms of reduction in splenomegaly and improvement of symptoms and quality of life. Areas covered: Data published about overall survival in the major randomized spon...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1273766

    authors: Massaro F,Molica M,Breccia M

    更新日期:2017-02-01 00:00:00

  • Analysis of Hb levels and degree of anemia in relation to genotype in 615 patients with hemoglobin H disease.

    abstract:OBJECTIVES:We analyzed hemoglobin (Hb) levels and degree of anemia in relation to genotype in patients with hemoglobin H (Hb H) disease, thereby providing a scientific basis for the prevention and treatment of Hb H disease in the Guangxi region of China. METHODS:Hb analysis was conducted in 615 patients using high per...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1803736

    authors: Luo S,Chen X,Chen L,Zhong Q,Wang Q,Xu Z,Huang J,Yan T,Tang N

    更新日期:2020-09-01 00:00:00

  • Thrombocytopenia in neonates with polycythemia: incidence, risk factors and clinical outcome.

    abstract:BACKGROUND:Polycythemia occurs in 1 to 5% of neonates and is associated with complications, including an increased risk of thrombocytopenia. OBJECTIVE:To evaluate incidence, risk factors, management and outcome of thrombocytopenia in neonates with polycythemia. STUDY DESIGN:All neonates with polycythemia admitted to ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/17474086.2015.997705

    authors: Vlug RD,Lopriore E,Janssen M,Middeldorp JM,Rath ME,Smits-Wintjens VE

    更新日期:2015-02-01 00:00:00

  • Transfusion strategies in patients undergoing stem-cell transplantation.

    abstract::Hemopoietic stem-cell transplant patients may require intensive blood component support. Complications of transfusions include transmission of viral and bacterial infections, transfusion-associated graft-versus-host disease and transfusion-related acute lung injury. Alloimmunization to red cell antigens may cause diff...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.11.14

    authors: Radia R,Pamphilon D

    更新日期:2011-04-01 00:00:00

  • Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient.

    abstract::The incidence of non-Hodgkin's lymphoma (NHL) is increasing among all age groups, with a median age at diagnosis of 67 years. With the increase in the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients. Therapy in elderly patients is affected by ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.7

    authors: Ninan MJ,Morrison VA

    更新日期:2009-04-01 00:00:00

  • Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma.

    abstract:INTRODUCTION:Immune surveillance is the dynamic process whereby the immune system identifies and kills tumor cells based on their aberrant expression of stress-related surface molecules or presentation of tumor neoantigens. It plays a crucial role in controlling the initiation and progression of hematologic cancers suc...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1755958

    authors: Nesic M,El-Galaly TC,Bøgsted M,Pedersen IS,Dybkær K

    更新日期:2020-06-01 00:00:00

  • What does the 'Cochrane database of systematic reviews' tell us about hemophilia?

    abstract::Introduction: The purpose of this article is to review which data about hemophilia are currently provided by the Cochrane database of systematic reviews (CDBSR). Methodological consideration: All statements about hemophilia in the Cochrane Collaboration are based on evidence generated in randomized controlled clinical...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2019.1676718

    authors: Rodriguez-Merchan EC

    更新日期:2019-11-01 00:00:00

  • Eltrombopag for the treatment of immune thrombocytopenia.

    abstract::Chronic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count that has persisted for more than 12 months. Patients with severe, symptomatic disease may have significant morbidity and require treatment. Historically, the underlying cause of ITP was believed to be accelerated plat...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/ehm.11.25

    authors: Cheng G

    更新日期:2011-06-01 00:00:00

  • Ferumoxytol for the treatment of iron deficiency anemia.

    abstract:INTRODUCTION:Ferumoxytol is a superparamagnetic molecule originally developed as a contrast agent for magnetic resonance imaging. Elemental iron is contained within the carbohydrate core and is released slowly after infusion allowing a large dose of iron to be administered in a short period of time. Ferumoxytol, origin...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1518712

    authors: Auerbach M,Chertow GM,Rosner M

    更新日期:2018-10-01 00:00:00

  • Diagnosis and management of catastrophic antiphospholipid syndrome.

    abstract:INTRODUCTION:Catastrophic antiphospholipid syndrome (CAPS) is a rare, life-threatening disease. In 1992, Asherson defined it as a widespread coagulopathy related to the antiphospholipid antibodies (aPL). CAPS requires rapid diagnosis and prompt initiation of treatment. Areas covered: This paper discusses all aspects of...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1300522

    authors: Carmi O,Berla M,Shoenfeld Y,Levy Y

    更新日期:2017-04-01 00:00:00

  • Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

    abstract::Many patients with acute myeloid leukemia will eventually develop refractory or relapsed disease. In the absence of standard therapy for this population, there is currently an urgent unmet need for novel therapeutic agents. Targeted therapy with small molecule inhibitors represents a new therapeutic intervention that ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.932687

    authors: Al-Hussaini M,DiPersio JF

    更新日期:2014-08-01 00:00:00

  • An update on biology, diagnosis and treatment of primary plasma cell leukemia.

    abstract:INTRODUCTION:Primary plasma cell leukemia (PPCL) is one of the most aggressive hematological malignancies. The prognosis of PPCL patients remains poor, although some improvements have been made in recent years. Areas covered: In this review recent clinical and biological advances in PPCL are reported. Some recommendati...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1598258

    authors: Musto P,Statuto T,Valvano L,Grieco V,Nozza F,Vona G,Bochicchio GB,La Rocca F,D'Auria F

    更新日期:2019-04-01 00:00:00

  • Diagnosis and management of factor V Leiden.

    abstract:INTRODUCTION:The discovery of the factor V Leiden (FVL) missense mutation (Arg506Gln) causing factor V resistance to the anticoagulant action of activated protein C was a landmark that allowed a better understanding of the basis of inherited thrombotic risk. FVL mutation is currently the most common known hereditary de...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2016.1249364

    authors: Campello E,Spiezia L,Simioni P

    更新日期:2016-12-01 00:00:00

  • Combining gene therapy and fetal hemoglobin induction for treatment of β-thalassemia.

    abstract::β-thalassemias are caused by nearly 300 mutations of the β-globin gene, leading to a low or absent production of adult hemoglobin (HbA). Two major therapeutic approaches have recently been proposed: gene therapy and induction of fetal hemoglobin (HbF) with the objective of achieving clinically relevant levels of Hbs. ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/ehm.13.24

    authors: Breda L,Rivella S,Zuccato C,Gambari R

    更新日期:2013-06-01 00:00:00

  • Safety issues and management of toxicities associated with new treatments for multiple myeloma.

    abstract:INTRODUCTION:In the last decade, the availability of new drugs for the treatment of Multiple Myeloma (MM) significantly improved patients' outcomes, but also raised attention towards a new spectrum of adverse events. Recently, four novel agents with different mechanisms of action (carfilzomib, elotuzumab, daratumumab a...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/17474086.2017.1284584

    authors: Brioli A,Mügge LO,Hochhaus A,Von Lilienfeld-Toal M

    更新日期:2017-03-01 00:00:00

  • Platelet dose for prophylactic platelet transfusions.

    abstract::Although guidelines exist to deal with some aspects of platelet transfusion practice, many important clinical issues have not been addressed in large randomized controlled trials (RCTs). Slichter et al. conducted a RCT of prophylactic platelet transfusions to determine the effects of the dose of platelets on clinical ...

    journal_title:Expert review of hematology

    pub_type: 评论,杂志文章

    doi:10.1586/ehm.10.36

    authors: Cid J,Lozano M

    更新日期:2010-08-01 00:00:00

  • Determination of the anticoagulant effects of new oral anticoagulants: an unmet need.

    abstract::Thromboembolic diseases require anticoagulation for their prevention and treatment. New oral anticoagulants, specifically direct factor Xa and thrombin inhibitors, were developed to overcome the limitations of conventional anticoagulants. Their benefit has been demonstrated using fixed doses without laboratory-guided ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.11.79

    authors: Harenberg J,Marx S,Erdle S,Krämer R

    更新日期:2012-02-01 00:00:00

  • Ponatinib in the therapy of chronic myeloid leukemia.

    abstract:INTRODUCTION:Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder that has become the neoplastic poster child for understanding the disease biology of a malignant disease and targeting effective therapy. The targeted therapy of BCR-ABL inhibition by tyrosine kinase inhibitors (TKI) has provided the epitome f...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2016.1232163

    authors: Poch Martell M,Sibai H,Deotare U,Lipton JH

    更新日期:2016-10-01 00:00:00